본문 바로가기
KERD
논문KCI 등재

Clinical Validation of the Unparalleled Sensitivity of the Novel Allele-Discriminating Priming System Technology–Based EGFR Mutation Assay in Patients with Operable Non–Small Cell Lung Cancer

최용수|박수지|이진선|김성현|이병철|강정희|김진국|최윤라|조민섭|최지현|박지은|김홍관|심영목|박일현|손대순|전영정
대한암학회 (Korean Cancer Association)|2024.01|Cancer Research and Treatment|제56권 제1호|pp. 81-91|DOI 10.4143/crt.2023.408

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

EGFR mutationNon-small-cell lung carcinomaEGFR-TKI treatmentADPS EGFR Mutation Test KitCompanion diagnostics
주제분류의학일반

초록

Purpose Recently, we developed allele-discriminating priming system (ADPS) technology. This method increases the sensitivity of conventional quantitative polymerase chain reaction up to 100 folds, with limit of detection, 0.01%, with reinforced specificity. This prospective study aimed to develop and validate the accuracy of ADPS epidermal growth factor receptor (EGFR) Mutation Test Kit using clinical specimens. Materials and Methods In total 189 formalin-fixed paraffin-embedded tumor tissues resected from patients with non–small cell lung cancer were used to perform a comparative evaluation of the ADPS EGFR Mutation Test Kit versus the cobas EGFR Mutation Test v2, which is the current gold standard. When the two methods had inconsistent results, next-generation sequencing–based CancerSCAN was utilized as a referee. Results The overall agreement of the two methods was 97.4% (93.9%-99.1%); the positive percent agreement, 95.0% (88.7%-98.4%); and the negative percent agreement, 100.0% (95.9%-100.0%). EGFR mutations were detected at a frequency of 50.3% using the ADPS EGFR Mutation Test Kit and 52.9% using the cobas EGFR Mutation Test v2. There were 10 discrepant mutation calls between the two methods. CancerSCAN reproduced eight ADPS results. In two cases, mutant allele fraction was ultra-low at 0.02% and 0.06%, which are significantly below the limit of detection of the cobas assay and CancerSCAN. Based on the EGFR genotyping by ADPS, the treatment options could be switched in five patients. Conclusion The highly sensitive and specific ADPS EGFR Mutation Test Kit would be useful in detecting the patients who have lung cancer with EGFR mutation, and can benefit from the EGFR targeted therapy.

Abstract

Purpose Recently, we developed allele-discriminating priming system (ADPS) technology. This method increases the sensitivity of conventional quantitative polymerase chain reaction up to 100 folds, with limit of detection, 0.01%, with reinforced specificity. This prospective study aimed to develop and validate the accuracy of ADPS epidermal growth factor receptor (EGFR) Mutation Test Kit using clinical specimens. Materials and Methods In total 189 formalin-fixed paraffin-embedded tumor tissues resected from patients with non–small cell lung cancer were used to perform a comparative evaluation of the ADPS EGFR Mutation Test Kit versus the cobas EGFR Mutation Test v2, which is the current gold standard. When the two methods had inconsistent results, next-generation sequencing–based CancerSCAN was utilized as a referee. Results The overall agreement of the two methods was 97.4% (93.9%-99.1%); the positive percent agreement, 95.0% (88.7%-98.4%); and the negative percent agreement, 100.0% (95.9%-100.0%). EGFR mutations were detected at a frequency of 50.3% using the ADPS EGFR Mutation Test Kit and 52.9% using the cobas EGFR Mutation Test v2. There were 10 discrepant mutation calls between the two methods. CancerSCAN reproduced eight ADPS results. In two cases, mutant allele fraction was ultra-low at 0.02% and 0.06%, which are significantly below the limit of detection of the cobas assay and CancerSCAN. Based on the EGFR genotyping by ADPS, the treatment options could be switched in five patients. Conclusion The highly sensitive and specific ADPS EGFR Mutation Test Kit would be useful in detecting the patients who have lung cancer with EGFR mutation, and can benefit from the EGFR targeted therapy.

참고문헌 (30)

  1. Mok TS, "Personalized medicine in lung cancer : what we need to know", Nat Rev Clin Oncol, 8, pp.661~668 (2011)
  2. Hensing T, "A personalized treat ment for lung cancer : molecular pathways, targeted therapies, and genomic characterization", Adv Exp Med Biol, 799, pp.85117~ (2014)
  3. Salk JJ, "Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations", Nat Rev Genet, 19, pp.269~285 (2018)
  4. Li X, "Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung can cer", Oncotarget, 8, pp.100801~100818 (2017)
  5. Nakamura H, "Accuracy of the cobas EGFR mutation assay in non-small-cell lung cancer compared with three laboratory-developed tests", Clin Lung Cancer, 19, pp.170~174 (2018)
  6. Syed YY, "therascreen(R)EGFR RGQ PCR Kit : A companion diagnostic for afatinib and gefitinib in non-small cell lung cancer", Mol Diagn Ther, 20, pp.191~198 (2016)
  7. Kim SS, "Droplet digital PCR-based EGFR mutation detection with an internal quality control index to determine the quality of DNA", Sci Rep, 8, pp.543~ (2018)
  8. Shin HT, "Prevalence and detection of low-allele-fraction variants in clinical cancer samples", Nat Commun, 8, pp.1377~ (2017)
  9. Lee C, "A method to evaluate the quality of clinical gene-panel sequencing data for single-nucleotide variant detection", J Mol Diagn, 19, pp.651~658 (2017)
  10. Huang JK, "A new primer construc tion technique that effectively increases amplification of rare mutant templates in samples", BMC Biotechnol, 19, pp.62~ (2019)
  11. Kramer FR, "SuperSelective primer pairs for sen sitive detection of rare somatic mutations", Sci Rep, 11, pp.22384~ (2021)
  12. Lim Y, "Modi f ied Taq DNA polymerase for allele-specific ultra-sensitive detection of genetic variants", J Mol Diagn, 24, pp.1128~1142 (2022)
  13. Rosell R, "Erlotinib versus standard chemotherapy as first line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC) : a multicentre, open-label, randomised phase 3 trial", Lancet On col, 13, pp.239~246 (2012)
  14. Sequist LV, "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations", J Clin Oncol, 31, pp.3327~3334 (2013)
  15. Soria JC, "Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer", N Engl J Med, 378, pp.113~125 (2018)
  16. Ramalingam SS, "Overall survival with osimertinib in untreat ed, EGFR-mutated advanced NSCLC", N Engl J Med, 382, pp.41~50 (2020)
  17. Kancha RK, "Functional analysis of epidermal growth factor receptor(EGFR)muta tions and potential implications for EGFR targeted therapy", Clin Cancer Res, 15, pp.460~467 (2009)
  18. Lee CK, "Impact of specific epidermal growth factor receptor(EGFR)mutations and clinical characteristics on outcomes after treat ment with EGFR tyrosine kinase inhibitors versus che-mo therapy in EGFR-mutant lung cancer : a meta-analysis", J Clin Oncol, 33, pp.1958~1965 (2015)
  19. Gazdar AF, "Activating and resistance mutations of EGFR in non-small-cell lung cancer : role in clinical response to EGFR tyrosine kinase inhibitors", Oncogene, 28(Suppl 1), pp.S24~S31 (2009)
  20. Hsu WH, "Overview of current systemic management of EGFR-mutant NSCLC", Ann Oncol, 29, pp.i3~i9 (2018)
  21. Mok TS, "Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer", N Engl J Med, 376, pp.629~640 (2017)
  22. Zhou C, "Erlo tinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer(OPTIMAL, CTONG-0802) : a multicentre, open-label, randomised, phase 3 study", Lancet Oncol, 12, pp.735~742 (2011)
  23. Maemondo M, "Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR", N Engl J Med, 362, pp.2380~2388 (2010)
  24. Huang YH, "The impact of different first-line EGFR-TKIs on the clini cal outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M", Sci Rep, 11, pp.12084~ (2021)
  25. Arcila ME, "EGFR exon 20 insertion mutations in lung adenocarcino mas : prevalence, molecular heterogeneity, and clinicopatho logic characteristics", Mol Cancer Ther, 12, pp.220~229 (2013)
  26. Yang JC, "Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mu tations : a combined post-hoc analysis of LUX-Lung 2, LUX Lung 3, and LUX-Lung 6", Lancet Oncol, 16, pp.830~838 (2015)
  27. Rosell R, "Screening for epidermal growth factor receptor mutations in lung cancer", N Engl J Med, 361, pp.958~967 (2009)
  28. U.S. Food and Drug Administrastion, "FDA summary of safe ty and effectiveness data (SSED). Premarket approval (PMA)No. P120019. Cobas EGFR Mutation Test v2", U.S. Food and Drug Administration, ~ (2018)
  29. Reynolds JP, "EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration(FNA)at endobronchial ultrasound of non-small cell lung cancer(NSCLC)", Lung Cancer, 86, pp.158~163 (2014)
  30. Smouse JH, "EGFR mutations are detected comparably in cyto-logic and surgical pathology specimens of nonsmall cell lung can cer", Cancer, 117, pp.67~72 (2009)

관련 논문AI추천

Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer김규식, 김영철, 박철규, 신홍준, 오인재, 윤성훈, 장진선, 최유덕, 최하영대한암학회 · Cancer Research and Treatment2015 · 제47권 제4호Detection of Rare Mutations in EGFR-ARMS-PCR-Negative Lung Adenocarcinoma by Sanger SequencingAllen M. Chen, Chaoyue Liang, Chengzhi Zhou, Chenxian Liu, Haiyun Mo, Jiexia Zhang, Xiaohong Gan, Ying Liang, You You, Yuanbin Liu, Zhuolin Wu연세대학교의과대학 · Yonsei Medical Journal2018 · 제59권 제1호Tissue and Plasma-Based Highly Sensitive Blocker Displacement Amplicon Nanopore Sequencing for <i>EGFR</i> Mutations in Lung CancerChinachote Teerapakpinyo, Patinya Akkhasutthikun, Pattaraporn Nimsamer, Pavit Klomkliew, Pornchai Kaewsapsak, Pragwalai Chanchaem, Sunchai Payungporn, Suthida Visedthorn, Sutima Luangdilok대한암학회 · Cancer Research and Treatment2024 · 제56권 제2호Revolutionizing Non–Small Cell Lung Cancer Diagnosis: Ultra-High-Sensitive ctDNA Analysis for Detecting Hotspot Mutations with Long-term Stored Plasma성창옥, 이지영, 장세진, 전세연, 전하라, 천성민, 최창민대한암학회 · Cancer Research and Treatment2024 · 제56권 제2호Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of EGFR Mutations in Non-small Cell Lung Carcinoma and the Correlation with Clinical Responses to EGFR Tyrosine Kinase Inhibitor Treatment김지은, 김효진, 이현주, 정진행, Pingli Sun, Xianhua Xu, Yan Jin대한병리학회 · Journal of Pathology and Translational Medicine2013 · 제47권 제1호Analytical and Clinical Validation of a Highly Sensitive NGS-Based ctDNA Assay with Real-World Concordance in NSCLC경동수, 김동완, 김미소, 김범석, 김태민, 김태유, 김황필, 노한성, 방두희, 육정환, 이한백, 임유주대한암학회 · Cancer Research and Treatment2024 · 제56권 제3호

이 간행물의 다른 논문 (30건)

Intensity-Modulated Radiation Therapy for Uterine Cervical Cancer to Reduce Toxicity and Enhance Efficacy – an Option or a Must?: A Narrative Review이세원, 이성종, 김성환, 김애란, 이종훈pp. 1-17Longitudinal Changes in Smoking Behaviors and Cancer-Related Mortality Risk in Middle-aged Korean Women김선주, 박보영, 김소연, TRANTHIXUANMAIpp. 18-26Trends and Clinical Characteristics of Next-Generation Sequencing-Based Genetic Panel Tests: An Analysis of Korean Nationwide Claims Data박해용, 임현선, 김은경, 최윤라, 심효섭, 장미, 허자윤pp. 27-36A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial김규현, 이근욱, 안희경, 김진수, 이윤규, 안호정, 임선민, 안명주, 김범석, 김혜련, 이현우pp. 37-47Lazertinib versus Gefitinib as First-Line Treatment for EGFR-Mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset왕장영, 이윤규, 신상원, 최진혁, 이종석, 김진수, 심병용, 김주항, 민영주, 이기형, 이영주, 박건욱, 고윤호, 김동완, 최석영, 강진형, 조은경, 이경원, 전상훈, 이성숙, 이경희, 김상위, 안명주, 조병철pp. 48-60
원문 보기